Demographics and survival of a cohort of blood and breast cancer patients who developed heart failure following cancer treatment

Robyn Clark, A McCarthy, Munir Chowdhury, Narelle Berry, Shahid Ullah, Bogda Koczwara, J Atherton, David Roder

Research output: Contribution to journalMeeting Abstractpeer-review


Background/Aim: Cardiotoxicity resulting in heart failure is a devastating complication of cancer therapy. It is possible that a patient may survive cancer only to develop heart failure (HF), which is more deadly than cancer. The aim of this project was to profile the characteristics of patients at risk of cancer treatment induced heart failure.

Methods: Linked Health Data Analysis of Queensland Cancer Registry (QCR) from 1996-2009, Death Registry and Hospital Administration records for HF and chemotherapy admissions were reviewed. Index heart failure admission must have occurred after the date of cancer registry entry.

Results: A total of 15,987 patients were included in this analysis; 1,062 (6.6%) had chemotherapy+HF admission (51.4% Female) and 14,925 (93.4%) chemotherapy_no HF admission. Median age of chemotherapy+HF patients was 67 years (IQR 58 to 75) vs. 54 years (IQR 44 to 64) for chemotherapy_no HF admission. Chemotherapy+HF patients had increased risk of all cause mortality (HR 2.79 [95% CI 2.58-3.02] and 1.67 [95% CI, 1.54 to 1.81] after adjusting for age, sex, marital status, country of birth, cancer site and chemotherapy dose). Index HF admission occurred within one year of cancer diagnosis in 47% of HF patients with 80% of patinets having there index admission with 3 years. The number of chemotherapy cycles was not associated with significant reduction in survival time in chemotherapy+HF patients. Mean survival for heart failure patients was 5.3 years (95% CI, 4.99 - 5.62) vs.9.57 years (95% CI, 9.47-9.68) for chemotherapy_no HF admission patients.

Conclusion: All-cause mortality was 67% higher in patients diagnosed with HF following chemotherapy in adjusted analysis for covariates. Methods to improve and better coordinate of the interdisciplinary care for cancer patients with HF involving cardiologists and oncologists are required, including evidence-based guidelines for the comprehensive assessment, monitoring and management of this cohort.
Original languageEnglish
Article number12134
Issue numberSuppl. 2
Publication statusPublished - 25 Nov 2014
EventAmerican Heart Association's 2014 Scientific Sessions and Resuscitation Science Symposium -
Duration: 15 Nov 2014 → …


  • Cardiotoxicity
  • heart failure
  • cancer therapy


Dive into the research topics of 'Demographics and survival of a cohort of blood and breast cancer patients who developed heart failure following cancer treatment'. Together they form a unique fingerprint.

Cite this